Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 13/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278145 | 0.90 | SMN1; SMN2 (0.47) | BDKRB1KCNH2SMN1; SMN2USP30 | |
| SCHEMBL3273902 | 0.90 | BDKRB1 (0.59) | BDKRB1KCNH2SMN1; SMN2ALDH1A1 | |
| SCHEMBL3280606 | 0.88 | BDKRB1 (0.62) | BDKRB1KCNH2SMN1; SMN2ALDH1A1 | |
| SCHEMBL3274343 | 0.88 | SMN1; SMN2 (0.48) | BDKRB1KCNH2SMN1; SMN2USP30 | |
| SCHEMBL15103718 | 0.88 | BDKRB1 (0.44) | BDKRB1KCNH2 | |
| SCHEMBL3049821 | 0.88 | BDKRB1 (0.56) | BDKRB1KCNH2ALDH1A1 | |
| SCHEMBL3049816 | 0.88 | BDKRB1 (0.56) | BDKRB1KCNH2ALDH1A1 | |
| SCHEMBL15103982 | 0.88 | BDKRB1 (0.55) | BDKRB1KCNH2ALDH1A1 | |
| SCHEMBL3275545 | 0.87 | BDKRB1 (0.57) | BDKRB1KCNH2ALDH1A1 | |
| SCHEMBL3278506 | 0.87 | BDKRB1 (0.57) | BDKRB1KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076491-B1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-07-17 | — | — | EP | claimed |
| US-8481527-B2 | Benzamide derivatives as bradykinin antagonists | RICHTER GEDEON NYRT. (HU) | 2013-07-09 | — | — | US | claimed |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-08 | — | — | US | claimed |
| EP-2076491-B1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | BDKRB1 1/4885KCNH2 55/4885SMN1; SMN2 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.